Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Bayer Completes Phase I of China TCM/OTC Production Plant

publication date: Jan 14, 2016
Bayer AG completed construction of the first phase of a $213 million China consumer healthcare manufacturing facility in Yunan province. The plant will make TCM and OTC products. In 2014, Bayer paid $578 million to acquire Dihon Pharma, a TCM/OTC company that had already begun building the facility. Bayer will use the plant to expand capacity for Dihon's products initially and its own later. The plant will be Bayer's second largest production facility for consumer healthcare in Asia and will become a center for Bayer's global OTC business. More details....

Stock Symbol: (XETRA: BAYN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here